A combination coronavirus and influenza vaccine will be tested, according to Pfizer-BioNTech, which might lead to increased vaccination rates for both diseases.
According to a firm statement, the mRNA-based combination vaccination candidate was expected to advance to a phase one study in the United States with 180 participants.
According to Annaliesa Anderson, head of vaccine research and development at US pharmaceutical company Pfizer, the vaccination “may simplify immunization processes against these two respiratory viruses, perhaps leading to greater vaccine uptake for both illnesses.”
“Even with the seasonal influenza vaccinations currently available, the impact of this virus remains severe worldwide, resulting in thousands of hospitalizations and deaths yearly.”
One of the most popular vaccinations to prevent diseases was created by Pfizer and its German partner BioNTech to comabat COVID-19.
Rival vaccine makers Moderna and Novavax have also been testing combined inoculations against Covid and flu.